Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible), announces the publication date for its 2024 results:

 

Publication

   

Date

 

2024 results

   

April 29, 2025*

*Distribution after the close of trading

About Median Technologies: Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.

MEDIAN TECHNOLOGIES Emmanuelle Leygues VP, Corporate Marketing & Financial Communications +33 6 10 93 58 88 emmanuelle.leygues@mediantechnologies.com

Investors Ghislaine Gasparetto SEITOSEI ACTIFIN +33 6 21 10 49 24 ghislaine.gasparetto@seitosei-actifin.com

U.S. media & investors Chris Maggos COHESION BUREAU +41 79 367 6254 chris.maggos@cohesionbureau.com

Press Caroline Carmagnol ALIZE RP +33 6 64 18 99 59 median@alizerp.com

Median Technologies (EU:ALMDT)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Median Technologies 차트를 더 보려면 여기를 클릭.
Median Technologies (EU:ALMDT)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Median Technologies 차트를 더 보려면 여기를 클릭.